Gujarat Themis Biosyn Ltd

- Current sales closely match production; capacity utilization is above 100% due to prior inventory. - Strong demand outlook for the rest of FY24; aiming to maintain or improve capacity utilization from last year's 75-80%. - Expected revenue growth tied to full capacity utilization and new API block commissioning from December 2023. - New API plant focusing on Rifapentine with flexible multi-purpose production capacity (~7 tons/month). - Anticipate significant revenue increase once API revenues start, but exact growth magnitude is uncertain. - Earlier guided 25-30% revenue growth in FY24 if 100% capacity utilization is sustained. - Inventory normalized; no immediate benefit from inventory build-up expected going forward. - Long-term growth boosted by expanding fermentation-based product portfolio and new CAPEX plans, which may exceed Rs. 200 crores. - Market shifts like Rifapentine adoption and rifaximin patent expiry could positively impact volumes.

- The company anticipates strong demand and expects better capacity utilization this year compared to the previous 75%-80% last year. - Revenues for FY24 are expected to grow if 100% capacity utilization is achieved, targeting around Rs.190-200 crores. - Growth is linked to selling what is produced, with no backlog inventory, implying stable real-time sales. - API block commissioning by December 2023 is expected to generate incremental revenues starting FY25. - Rifapentine production presents significant growth potential with promising pricing and market demand. - EBITDA margins were impacted due to increased R&D and skilled workforce investments. - EPS for Q2 FY24 was reported at Rs.8.63 per share; half-year EPS stands at Rs.20.83. - CAPEX associated with growth is expected to increase (possibly doubling from Rs.200 crores), funded by internal accruals and debt-equity mix. - R&D expenses may fluctuate, reflecting developmental activity levels.

- The transcript does not explicitly mention the exact current or expected order book or pending orders in numerical terms. - Dr. Sachin Patel indicated strong demand currently with no backlog of inventory, implying orders are being fulfilled as produced. - For Rifapentine, initial Indian government tenders indicate demand around 30-40 MT annually, possibly higher. - The company anticipates growth if 100% capacity utilization is maintained, targeting Rs.190-200 crores top-line for FY24. - Production matches sales currently; no carryover inventory suggests orders are being met promptly. - New API capacity commissioning expected by December 2023 aims to support future order fulfillment and revenue growth. - Demand for their products, including emerging ones like Rifapentine, is described as strong and solid for the near term.

- Gujarat Themis Biosyn Limited is planning significant CAPEX over the next three years, likely increasing beyond the initially planned Rs. 200 crores. - Funding for this CAPEX will be partially through internal accruals. - The company will also pursue debt-equity financing but has not finalized the exact mix of debt or equity. - A decision on the mode of funding (debt, equity, or mix) is expected within the next six to nine months. - No specific mention of immediate fundraising via equity dilution; evaluations are ongoing.

- Phase-I CAPEX of around Rs. 80 crores is near completion with some additional minor spend expected until plant commissioning in December 2023. - Construction of new API block and R&D block to be commissioned by December 2023. - Additional fermentation capacity expansion underway, expected ready by 2025. - Total CAPEX planned over three years initially estimated at Rs. 200 crores but now expected to be at least double that amount, possibly more. - Funding will be through a mix of internal accruals and debt-equity options under consideration over the next 6-9 months. - The company is applying for incentives from the Gujarat Government Biotechnology Promotion Board but not participating in the central government's PLI scheme. - New facilities will comply with global regulatory norms targeting both domestic and export markets.